Afatinib (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Afatinib" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

8nih.gov

4^th place

8^th place

3doi.org

2^nd place

5^th place

1cbz.si

low place

607^th place

1termania.net

low place

34^th place

1fda.gov

447^th place

409^th place

1tga.gov.au

3,984^th place

2,156^th place

1handle.net

102^nd place

416^th place

1medicines.org.uk

3,823^rd place

3,244^th place

1web.archive.org

1^st place

2^nd place

1europa.eu

68^th place

28^th place

1medscape.com

719^th place

152^nd place

cbz.si

http://www.cbz.si/cbz/bazazdr2.nsf/Search?SearchView&Query=(%5BJENALISTI%5D=1)+(%5BSEZNAMUCINKNAZIV%5D=_afatinib*)&SearchOrder=4&SearchMax=301 Centralna baza zdravil, vpogled: 10. 12. 2012.

doi.org

Vavalà T (2017). »Role of afatinib in the treatment of advanced lung squamous cell carcinoma«. Clinical Pharmacology. 9: 147–157. doi:10.2147/CPAA.S112715. PMC 5709991. PMID 29225480.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, in sod. (Junij 2012). »A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab«. Breast Cancer Research and Treatment. 133 (3): 1057–65. doi:10.1007/s10549-012-2003-y. PMC 3387495. PMID 22418700.
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, in sod. (Avgust 2008). »BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models«. Oncogene. 27 (34): 4702–11. doi:10.1038/onc.2008.109. PMC 2748240. PMID 18408761.

europa.eu

ema.europa.eu

»Giotrif : EPAR -Product Information« (PDF). European Medicines Agency. Boehringer Ingelheim International GmbH. 16. oktober 2013. Arhivirano iz prvotnega spletišča (PDF) dne 4. februarja 2014. Pridobljeno 28. januarja 2014.

fda.gov

accessdata.fda.gov

»Gilotrif (afatinib)« (PDF). US Food and Drug Administration. Pridobljeno 11. marca 2021.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

medicines.org.uk

»Giotrif 20 mg film-coated tablets – Summary of Product Characteristics (SPC)«. electronic Medicines Compendium. Boehringer Ingelheim Limited. 20. januar 2014. Pridobljeno 28. januarja 2014.

medscape.com

reference.medscape.com

»Gilotrif (afatinib) dosing, indications, interactions, adverse effects, and more«. Medscape Reference. WebMD. Pridobljeno 28. januarja 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Minkovsky N, Berezov A (december 2008). »BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors«. Current Opinion in Investigational Drugs. 9 (12): 1336–46. PMID 19037840.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Vavalà T (2017). »Role of afatinib in the treatment of advanced lung squamous cell carcinoma«. Clinical Pharmacology. 9: 147–157. doi:10.2147/CPAA.S112715. PMC 5709991. PMID 29225480.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, in sod. (Junij 2012). »A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab«. Breast Cancer Research and Treatment. 133 (3): 1057–65. doi:10.1007/s10549-012-2003-y. PMC 3387495. PMID 22418700.
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, in sod. (Avgust 2008). »BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models«. Oncogene. 27 (34): 4702–11. doi:10.1038/onc.2008.109. PMC 2748240. PMID 18408761.

ncbi.nlm.nih.gov

Vavalà T (2017). »Role of afatinib in the treatment of advanced lung squamous cell carcinoma«. Clinical Pharmacology. 9: 147–157. doi:10.2147/CPAA.S112715. PMC 5709991. PMID 29225480.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, in sod. (Junij 2012). »A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab«. Breast Cancer Research and Treatment. 133 (3): 1057–65. doi:10.1007/s10549-012-2003-y. PMC 3387495. PMID 22418700.
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, in sod. (Avgust 2008). »BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models«. Oncogene. 27 (34): 4702–11. doi:10.1038/onc.2008.109. PMC 2748240. PMID 18408761.

dailymed.nlm.nih.gov

»Gilotrif (afatinib) tablet, film coated«. DailyMed. Boehringer Ingelheim Pharmaceuticals, Inc. 18. oktober 2019. Pridobljeno 4. novembra 2020.

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/8333448/afatinib?query=afatinib&SearchIn=All Slovenski medicinski e-slovar, vpogled: 10. 12. 2021.

tga.gov.au

ebs.tga.gov.au

»Giotrif Afatinib (as afatinib dimaleate)« (PDF). TGA eBusiness Services. Boehringer Ingelheim Pty Limited. 7. november 2013. Pridobljeno 28. januarja 2014.

web.archive.org

»Giotrif : EPAR -Product Information« (PDF). European Medicines Agency. Boehringer Ingelheim International GmbH. 16. oktober 2013. Arhivirano iz prvotnega spletišča (PDF) dne 4. februarja 2014. Pridobljeno 28. januarja 2014.